Phase II trial of nilotinib in PDGFR-alpha-enriched recurrent high-grade gliomas
Nilotinib was well tolerated with limited benefit in this enriched population of patients. Further studies are warranted to determine the clinical benefit in patients in earlier lines of treatment. <b>Trial registration number:</b> NCT01140568, registered 08 June 2010.
Authors
- Natsuko Nomura
- David Piccioni (ORCID: https://orcid.org/0000-0001-6006-0126)
- Santosh Kesari (ORCID: https://orcid.org/0000-0003-3772-6000)
- Lara Rose
- Tiffany Juarez (ORCID: https://orcid.org/0000-0002-1736-9774)
Institutions
- California College San Diego (US)
- UC San Diego Health System (US)
- Saint John's Health Center (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf150
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- National Institutes of Health